{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T23:19:26Z","timestamp":1790983166677,"version":"4.1.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,2]]},"DOI":"10.7759\/cureus.113803","type":"journal-article","created":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:12:31Z","timestamp":1785697951000},"source":"Crossref","is-referenced-by-count":1,"title":["The Silent Valve Culprit: A Case Report and Literature Review of Isolated Cabergoline-Induced Mitral Regurgitation"],"prefix":"10.7759","author":[{"given":"Hiba","family":"Haouani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiba","family":"Elbakkali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Najlaa","family":"Belharty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Latifa","family":"Oukerraj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Cherti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"79","author":"Heidenreich PA","year":"2022","unstructured":"Heidenreich PA, Bozkurt B, Aguilar D, et al.. 2022 AHA\/ACC\/HFSA Guideline for the Management of Heart Failure: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 2022, 79:e263-421. 10.1016\/j.jacc.2021.12.012","journal-title":"J Am Coll Cardiol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2013.02.003","article-title":"Drug-induced valvular heart disease: an update","volume":"106","author":"Andrejak M","year":"2013","unstructured":"Andrejak M, Tribouilloy C. Drug-induced valvular heart disease: an update. Arch Cardiovasc Dis. 2013, 106:333-9. 10.1016\/j.acvd.2013.02.003","journal-title":"Arch Cardiovasc Dis"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1055\/s-0032-1331580","article-title":"Cardiac surgery for ergotamine-induced multivalvular heart disease","volume":"61","author":"Lazopoulos G","year":"2013","unstructured":"Lazopoulos G, Papaioannou G, Kantartzis M. Cardiac surgery for ergotamine-induced multivalvular heart disease. Thorac Cardiovasc Surg. 2013, 61:435-7. 10.1055\/s-0032-1331580","journal-title":"Thorac Cardiovasc Surg"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2025.10.160","article-title":"Valvular heart disease: current status in Morocco","volume":"1","author":"Siwane H","year":"2026","unstructured":"Siwane H, Ettachfini T, Bouziane M, et al.. Valvular heart disease: current status in Morocco. Arch Cardiovasc Dis. 2026, 1:36. 10.1016\/j.acvd.2025.10.160","journal-title":"Arch Cardiovasc Dis"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2009.01916.x","article-title":"Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy","volume":"39","author":"Pullan PT","year":"2009","unstructured":"Pullan PT. Dopamine agonists, Dopplers and doubt: cabergoline-associated cardiac valvulopathy. Intern Med J. 2009, 39:213-5. 10.1111\/j.1445-5994.2009.01916.x","journal-title":"Intern Med J"},{"key":"ref6","article-title":"Drug-induced valvular heart disease","author":"Ceron C","year":"2026","unstructured":"Ceron C, Goyal A, Makaryus AN. Drug-induced valvular heart disease. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2026."},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.102.23.2836","article-title":"Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications","volume":"102","author":"Rothman RB","year":"2000","unstructured":"Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ, Roth BL. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation. 2000, 102:2836-41. 10.1161\/01.cir.102.23.2836","journal-title":"Circulation"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/j.parkreldis.2023.105357","article-title":"Levodopa, homocysteine and Parkinson's disease: what's the problem?","volume":"109","author":"Ahlskog JE","year":"2023","unstructured":"Ahlskog JE. Levodopa, homocysteine and Parkinson's disease: what's the problem?. Parkinsonism Relat Disord. 2023, 109:105357. 10.1016\/j.parkreldis.2023.105357","journal-title":"Parkinsonism Relat Disord"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine","volume":"337","author":"Connolly HM","year":"1997","unstructured":"Connolly HM, Crary JL, McGoon MD, Hensrud DD, Edwards BS, Edwards WD, Schaff HV. Valvular heart disease associated with fenfluramine-phentermine. N Engl J Med. 1997, 337:581-8. 10.1056\/NEJM199708283370901","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.eurheartj.a015324","article-title":"Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine","volume":"18","author":"Wilke A","year":"1997","unstructured":"Wilke A, Hesse H, Hufnagel G, Maisch B. Mitral, aortic and tricuspid valvular heart disease associated with ergotamine therapy for migraine. Eur Heart J. 1997, 18:701. 10.1093\/oxfordjournals.eurheartj.a015324","journal-title":"Eur Heart J"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.1097\/00045415-200211000-00005","article-title":"Fibrotic valvular heart disease subsequent to bromocriptine treatment","volume":"10","author":"Serratrice J","year":"2002","unstructured":"Serratrice J, Disdier P, Habib G, et al.. Fibrotic valvular heart disease subsequent to bromocriptine treatment. Cardiol Rev. 2002, 10:334-6.","journal-title":"Cardiol Rev"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.4065\/77.12.1280","article-title":"Valvular heart disease in patients taking pergolide","volume":"77","author":"Pritchett AM","year":"2002","unstructured":"Pritchett AM, Morrison JF, Edwards WD, Schaff HV, Connolly HM, Espinosa RE. Valvular heart disease in patients taking pergolide. Mayo Clin Proc. 2002, 77:1280-6. 10.4065\/77.12.1280","journal-title":"Mayo Clin Proc"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000083985.00343.f2","article-title":"Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide","volume":"61","author":"Van Camp G","year":"2003","unstructured":"Van Camp G, Flamez A, Cosyns B, Goldstein J, Perdaens C, Schoors D. Heart valvular disease in patients with Parkinson's disease treated with high-dose pergolide. Neurology. 2003, 61:859-61. 10.1212\/01.wnl.0000083985.00343.f2","journal-title":"Neurology"},{"key":"ref14","article-title":"Clinical case of the month. Triple valvular dysfunction associated with long-term ergotamine therapy (Article in French)","volume":"58","author":"Goujon-Dubois J","year":"2003","unstructured":"Goujon-Dubois J, el Allaf D. Clinical case of the month. Triple valvular dysfunction associated with long-term ergotamine therapy (Article in French). Rev Med Liege. 2003, 58:70-2.","journal-title":"Rev Med Liege"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s0035-3787(04)70850-4","article-title":"Reversible cardiac valve abnormalities with pergolide treatment (Article in French)","volume":"160","author":"Calomne V","year":"2004","unstructured":"Calomne V, Dupuis MJM, Muller T, Kempinere F. Reversible cardiac valve abnormalities with pergolide treatment (Article in French). Rev Neurol (Paris. 2004, 160:81-2. 10.1016\/s0035-3787(04)70850-4","journal-title":"Rev Neurol (Paris"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20201","article-title":"Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists","volume":"19","author":"Horvath J","year":"2004","unstructured":"Horvath J, Fross RD, Kleiner-Fisman G, et al.. Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord. 2004, 19:656-62. 10.1002\/mds.20201","journal-title":"Mov Disord"},{"key":"ref17","article-title":"Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment guidelines in Parkinson's disease? (Article in Czech)","volume":"144","author":"Roth J","year":"2005","unstructured":"Roth J, Ulmanov\u00e1 O, R\u016fzicka E. Organ changes induced by ergot derivative dopamine agonist drugs: time to change treatment guidelines in Parkinson's disease? (Article in Czech). Cas Lek Cesk. 2005, 144:123-6.","journal-title":"Cas Lek Cesk"},{"key":"ref18","article-title":"Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use (Article in Dutch)","volume":"149","author":"van Strater AC","year":"2005","unstructured":"van Strater AC, Bax JJ, van Hilten JJ, Jukema JW. Severe insuffiency of the aortic and tricuspidal valves associated with pergolide use (Article in Dutch). Ned Tijdschr Geneeskd. 2005, 149:891-4.","journal-title":"Ned Tijdschr Geneeskd"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200511033531822","article-title":"Cabergoline-related severe restrictive mitral regurgitation","volume":"353","author":"Pinero A","year":"2005","unstructured":"Pinero A, Marcos-Alberca P, Fortes J. Cabergoline-related severe restrictive mitral regurgitation. N Engl J Med. 2005, 353:1976-7. 10.1056\/NEJM200511033531822","journal-title":"N Engl J Med"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMicm040922","article-title":"Images in clinical medicine. Four artificial heart valves","volume":"353","author":"Bijl M","year":"2005","unstructured":"Bijl M, van den Brink RB. Images in clinical medicine. Four artificial heart valves. N Engl J Med. 2005, 353:712. 10.1056\/NEJMicm040922","journal-title":"N Engl J Med"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1002\/mds.20813","article-title":"Valvular heart disease in a patient with Parkinson's disease treated with a low daily dose and a low cumulative dose of pergolide","volume":"21","author":"Chung EJ","year":"2006","unstructured":"Chung EJ, Yoon WT, Kim JY, Lee WY. Valvular heart disease in a patient with Parkinson's disease treated with a low daily dose and a low cumulative dose of pergolide. Mov Disord. 2006, 21:586-7. 10.1002\/mds.20813","journal-title":"Mov Disord"},{"key":"ref22","article-title":"Mitral valve replacement for cabergoline-related severe mitral regurgitation (Article in Japanese)","volume":"60","author":"Hanada T","year":"2007","unstructured":"Hanada T, Shimizu K, Murakami R, et al.. Mitral valve replacement for cabergoline-related severe mitral regurgitation (Article in Japanese). Kyobu Geka. 2007, 60:1018-21.","journal-title":"Kyobu Geka"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijcard.2006.07.020","article-title":"Mitral heart disease due to cabergoline","volume":"114","author":"Martin M","year":"2007","unstructured":"Martin M, Iglesias-Cubero G, Molina BD, De la Tassa CM. Mitral heart disease due to cabergoline. Int J Cardiol. 2007, 114:7-8.","journal-title":"Int J Cardiol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1093\/ejechocard\/jen191","article-title":"Valvular heart disease associated with taking low-dose pergolide for restless legs syndrome","volume":"9","author":"Worthington A","year":"2008","unstructured":"Worthington A, Thomas L. Valvular heart disease associated with taking low-dose pergolide for restless legs syndrome. Eur J Echocardiogr. 2008, 9:828-30. 10.1093\/ejechocard\/jen191","journal-title":"Eur J Echocardiogr"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.12968\/hmed.2008.69.1.28043","article-title":"Aortic regurgitation associated with cabergoline therapy","volume":"69","author":"Lyons K","year":"2008","unstructured":"Lyons K, Flannery D. Aortic regurgitation associated with cabergoline therapy. Br J Hosp Med (Lond). 2008, 69:50. 10.12968\/hmed.2008.69.1.28043","journal-title":"Br J Hosp Med (Lond)"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1111\/j.1445-5994.2009.01920.x","article-title":"Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma","volume":"39","author":"Cawood TJ","year":"2009","unstructured":"Cawood TJ, Bridgman P, Hunter L, Cole D. Low-dose cabergoline causing valvular heart disease in a patient treated for prolactinoma. Intern Med J. 2009, 39:266-7. 10.1111\/j.1445-5994.2009.01920.x","journal-title":"Intern Med J"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ancard.2008.05.022","article-title":"[An aortic insufficiency diagnosed under cabergoline (Article in French)","volume":"58","author":"Chagu\u00e9 F","year":"2009","unstructured":"Chagu\u00e9 F, Belleville I, Boujon B, Petit JM. [An aortic insufficiency diagnosed under cabergoline (Article in French). Ann Cardiol Angeiol (Paris). 2009, 58:189-91. 10.1016\/j.ancard.2008.05.022","journal-title":"Ann Cardiol Angeiol (Paris)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1186\/1749-8090-4-65","article-title":"Cardiac surgery in a patient with retroperitoneal fibrosis and heart valvulopathy, both due to pergolide medication for Parkinson's disease","volume":"4","author":"Apostolakis EE","year":"2009","unstructured":"Apostolakis EE, Baikoussis NG, Tselikos D, Koniari I, Prokakis C, Fokaeas E, Karanikolas M. Cardiac surgery in a patient with retroperitoneal fibrosis and heart valvulopathy, both due to pergolide medication for Parkinson's disease. J Cardiothorac Surg. 2009, 4:65. 10.1186\/1749-8090-4-65","journal-title":"J Cardiothorac Surg"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2007.11.043","article-title":"Severe mitral valve regurgitation with fatal cardiogenic shock in a patient on long-term cabergoline treatment","volume":"133","author":"Luedde M","year":"2009","unstructured":"Luedde M, Helmke B, Katus HA, Frey N. Severe mitral valve regurgitation with fatal cardiogenic shock in a patient on long-term cabergoline treatment. Int J Cardiol. 2009, 133:e97-8. 10.1016\/j.ijcard.2007.11.043","journal-title":"Int J Cardiol"},{"key":"ref30","article-title":"Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly","volume":"19","author":"Izgi C","year":"2010","unstructured":"Izgi C, Feray H, Cevik C, Saltan Y, Mansuroglu D, Nugent K. Severe tricuspid regurgitation in a patient receiving low-dose cabergoline for the treatment of acromegaly. J Heart Valve Dis. 2010, 19:797-800.","journal-title":"J Heart Valve Dis"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.4103\/2230-8210.81949","article-title":"Cabergoline-induced tricuspid regurgitation: case report and review of literature","volume":"15","author":"Bhat MH","year":"2011","unstructured":"Bhat MH, Mushtaq S, Saba S, Saif R, Ali G. Cabergoline-induced tricuspid regurgitation: case report and review of literature. Indian J Endocrinol Metab. 2011, 15:137-9. 10.4103\/2230-8210.81949","journal-title":"Indian J Endocrinol Metab"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-011-6077-y","article-title":"Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease","volume":"258","author":"Levin J","year":"2011","unstructured":"Levin J, Neudert J, Zwermann L, N\u00e4bauer M, B\u00f6tzel K. Reversible cardiac valve fibrosis secondary to treatment with high-dose cabergoline for Parkinson's disease. J Neurol. 2011, 258:2097-9. 10.1007\/s00415-011-6077-y","journal-title":"J Neurol"},{"key":"ref33","article-title":"Ergotamine-associated valvulopathy with recurrent chylous pleural effusion","volume":"39","author":"Bois JP","year":"2012","unstructured":"Bois JP, Ponnada VV, O'Cochlain DF, Brady PA, Edwards WD, Klarich KW. Ergotamine-associated valvulopathy with recurrent chylous pleural effusion. Tex Heart Inst J. 2012, 39:736-8.","journal-title":"Tex Heart Inst J"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.4081\/monaldi.2013.75","article-title":"A case of iatrogenic severe mitral regurgitation","volume":"80","author":"D'Aloia A","year":"2013","unstructured":"D'Aloia A, Piovanelli B, Rovetta R, Bonadei I, Vizzardi E, Curnis A, Metra M. A case of iatrogenic severe mitral regurgitation. Monaldi Arch Chest Dis. 2013, 80:133-6. 10.4081\/monaldi.2013.75","journal-title":"Monaldi Arch Chest Dis"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.06.065","article-title":"From headache to heartache: ergotamine-induced aortic and mitral valvulopathy","volume":"62","author":"Patel SM","year":"2013","unstructured":"Patel SM, Ohori NP, Badhwar V, Cavalcante JL. From headache to heartache: ergotamine-induced aortic and mitral valvulopathy. J Am Coll Cardiol. 2013, 62:2144. 10.1016\/j.jacc.2013.06.065","journal-title":"J Am Coll Cardiol"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.acvd.2012.06.007","article-title":"Multiple valvular regurgitation associated with bromocriptine therapy","volume":"107","author":"Cautres T","year":"2014","unstructured":"Cautres T, Cautres M, Mohty D. Multiple valvular regurgitation associated with bromocriptine therapy. Arch Cardiovasc Dis. 2014, 107:579-80. 10.1016\/j.acvd.2012.06.007","journal-title":"Arch Cardiovasc Dis"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2015.03.310","article-title":"Dynamic drug-induced organic mitral regurgitation during exercise echocardiography following chronic exposure to ergotamine","volume":"187","author":"Mar\u00e9chaux S","year":"2015","unstructured":"Mar\u00e9chaux S, Brahim YB, Ennezat PV, Delelis F, Tribouilloy C. Dynamic drug-induced organic mitral regurgitation during exercise echocardiography following chronic exposure to ergotamine. Int J Cardiol. 2015, 187:106-8. 10.1016\/j.ijcard.2015.03.310","journal-title":"Int J Cardiol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-220971","article-title":"Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective","volume":"2017","author":"Mohan N","year":"2017","unstructured":"Mohan N, Chia YY, Goh GH, Ting E, Teo K, Yeo TT. Cabergoline-induced fibrosis of prolactinomas: a neurosurgical perspective. BMJ Case Rep. 2017, 2017:10.1136\/bcr-2017-220971","journal-title":"BMJ Case Rep"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1210\/js.2018-00139","article-title":"The Third Case of Cabergoline-Associated Valvulopathy: The Value of Routine Cardiovascular Examination for Screening","volume":"2","author":"Caputo C","year":"2018","unstructured":"Caputo C, Prior D, Inder WJ. The Third Case of Cabergoline-Associated Valvulopathy: The Value of Routine Cardiovascular Examination for Screening. J Endocr Soc. 2018, 2:965-9. 10.1210\/js.2018-00139","journal-title":"J Endocr Soc"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1111\/echo.15506","article-title":"Long-term low-dose cabergoline usage: another association with cardiac valvulopathy","volume":"40","author":"Tessier S","year":"2023","unstructured":"Tessier S, Lipton BA, Arastu MI, Curiale AM, Longo S, Nanda S. Long-term low-dose cabergoline usage: another association with cardiac valvulopathy. Echocardiography. 2023, 40:61-4. 10.1111\/echo.15506","journal-title":"Echocardiography"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107866","article-title":"Fenfluramine repurposing from weight loss to epilepsy: what we do and do not know","volume":"226","author":"Odi R","year":"2021","unstructured":"Odi R, Invernizzi RW, Gallily T, Bialer M, Perucca E. Fenfluramine repurposing from weight loss to epilepsy: what we do and do not know. Pharmacol Ther. 2021, 226:107866. 10.1016\/j.pharmthera.2021.107866","journal-title":"Pharmacol Ther"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.5692\/clinicalneurol.48.486","article-title":"Two cases of patients with Parkinson's disease developing valvular heart disease while taking cabergoline (Article in Japanese)","volume":"48","author":"Sato T","year":"2008","unstructured":"Sato T, Kikuchi A, Onoue N, Hiramoto T, Oumi M, Onodera J. Two cases of patients with Parkinson's disease developing valvular heart disease while taking cabergoline (Article in Japanese). Rinsho Shinkeigaku. 2008, 48:486-91. 10.5692\/clinicalneurol.48.486","journal-title":"Rinsho Shinkeigaku"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)15945-X","article-title":"Treatment of Parkinson\u2019s disease with pergolide and relation to restrictive valvular heart disease","volume":"363","author":"Camp GV","year":"2004","unstructured":"Camp GV, Flamez A, Cosyns B, et al.. Treatment of Parkinson\u2019s disease with pergolide and relation to restrictive valvular heart disease. Lancet. 2004, 363:1179-83. 10.1016\/S0140-6736(04)15945-X","journal-title":"Lancet"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5922.2010.00169.x","article-title":"Regression of cardiac valvulopathy related to ergot-derived dopamine agonists","volume":"29","author":"Zanettini R","year":"2011","unstructured":"Zanettini R, Antonini A, Gatto G, Gentile R, Tesei S, Pezzoli G. Regression of cardiac valvulopathy related to ergot-derived dopamine agonists. Cardiovasc Ther. 2011, 29:404-10. 10.1111\/j.1755-5922.2010.00169.x","journal-title":"Cardiovasc Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/497748-the-silent-valve-culprit-a-case-report-and-literature-review-of-isolated-cabergoline-induced-mitral-regurgitation","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T19:12:32Z","timestamp":1785697952000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/497748-the-silent-valve-culprit-a-case-report-and-literature-review-of-isolated-cabergoline-induced-mitral-regurgitation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,2]]},"references-count":44,"URL":"https:\/\/doi.org\/10.7759\/cureus.113803","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,2]]}}}